Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 11/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 8/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637875 | 0.95 | PDGFRB (0.49) | PDGFRBACHEBACE1KRASPDGFRA | |
| SCHEMBL29611800 | 0.83 | KIT (0.52) | PDGFRBACHEBACE1KRASPDGFRA | |
| SCHEMBL16637964 | 0.83 | KIT (0.52) | PDGFRBACHEBACE1KRASPDGFRA | |
| SCHEMBL22631342 | 0.83 | ACHE (0.53) | PDGFRBACHEBACE1PDGFRAKIT | |
| SCHEMBL22631353 | 0.82 | ABL1 (0.45) | PDGFRBKRAS | |
| SCHEMBL22631414 | 0.82 | ACHE (0.67) | PDGFRBACHEBACE1PDGFRAKIT | |
| SCHEMBL17030873 | 0.81 | HTT (0.54) | PDGFRBACHEBACE1 | |
| SCHEMBL22029303 | 0.81 | KRAS (0.49) | PDGFRBACHEBACE1KRASPDGFRA | |
| SCHEMBL22631427 | 0.81 | KRAS (0.46) | KRAS | |
| SCHEMBL22631320 | 0.81 | ABL1 (0.40) | PDGFRBKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968214-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3735299-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-11-11 | — | — | EP | disclosed |
| US-20200115375-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115375-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PDGFRB 1004/4885ACHE 4874/4885BACE1 2715/4885 |
| US-10968214-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | PDGFRB 1004/4885ACHE 4874/4885BACE1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.